Borrowing from the lung cancer literature, where ALK alterations are more commonly seen, the mechanisms of resistance to ALK inhibitors include acquired resistance mutations in ALK; ALK gene amplification; the activation of downstream or bypass signaling pathways, including EGFR, MET, and MAPK; and the expression of drug efflux pumps [28,29,30,31]. This evidence concerns the gene EGFR and lung carcinoma.